Alector, Inc. (ALEC)

Alector's stock price has been impacted by several events. In October 2025, the Phase 3 INFRONT-3 trial failure for latozinemab led to workforce reduction and a stock plunge. In November 2025, an investigation was announced on behalf of Alector investors. Alector participated in the Bank of America CNS Therapeutics Conference in December 2025 and reported its Q4 and full year 2025 financial results in February 2026. In March 2026, Alector presented at the TD Cowen 46th Annual Health Care Conference. In April 2026, the Phase 2 PROGRESS-AD trial of nivisnebart was discontinued. In May 2026, Alector reported its Q1 2026 financial results, shifted its strategy toward the ABC platform, and established a $125 million at-the-market offering.

Alector, Inc.'s products and services are not subject to typical consumer demand seasonality. Demand for their therapies is driven by the prevalence of diseases like Alzheimer's, Parkinson's, and frontotemporal dementia, as well as the success of clinical trials and regulatory approvals.

Alector, Inc. is a clinical-stage biotechnology company focused on immuno-neurology to treat neurodegenerative diseases by leveraging the body's immune system. The company aims to develop therapies that remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Alector's pipeline includes product candidates like Latozinemab (AL001) for FTD-GRN, Nivisnebart (AL101/GSK4527226) for early Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, AL064 for Alzheimer's disease and other tauopathies, and the Alector Brain Carrier (ABC) platform to enhance drug delivery across the blood-brain barrier.

Alector, Inc. is headquartered in South San Francisco, California, USA. While its core operations are based in South San Francisco, its operational reach is global, driven by the need to conduct multinational clinical trials across North America, Europe, Australia, and potentially other regions.

Alector's brand reputation has likely been negatively impacted by the failure of the Phase 3 INFRONT-3 trial and the discontinuation of the Phase 2 PROGRESS-AD trial. These setbacks indicate challenges in their pipeline and raise concerns about their neurodegeneration research. The strategic pivot towards the ABC platform adds uncertainty as it remains clinically unvalidated.

Approximately 85.83% to 83.74% of Alector, Inc.'s stock is held by institutions, including TCG Crossover Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Individual insiders hold approximately 9.70% of the company's stock. Insiders have sold more stock than they have bought in the past three months.